PD-L1 Expression and Combined Status of PD-L1/PD-1–Positive Tumor Infiltrating Mononuclear Cell Density Predict Prognosis in Glioblastoma Patients
Jiheun Han, Yongkil Hong, Youn Soo Lee
J Pathol Transl Med. 2017;51(1):40-48.   Published online 2016 Dec 15     DOI: https://doi.org/10.4132/jptm.2016.08.31
Citations to this article as recorded by Crossref logo
The Prognostic and Therapeutic Value of PD-L1 in Glioma
Ruo Qiao Chen, Feng Liu, Xin Yao Qiu, Xiao Qian Chen
Frontiers in Pharmacology.2019;[Epub]     CrossRef
Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
Xin Wang, Gaochao Guo, Hui Guan, Yang Yu, Jie Lu, Jinming Yu
Journal of Experimental & Clinical Cancer Research.2019;[Epub]     CrossRef
Prognostic relevance of programmed cell death ligand 1 expression in glioblastoma
Kyu Sang Lee, Kyoungyul Lee, Sumi Yun, Seyoung Moon, Yujun Park, Jung Ho Han, Chae-Yong Kim, Hye Seung Lee, Gheeyoung Choe
Journal of Neuro-Oncology.2018; 136(3): 453.     CrossRef
Programmed Death-Ligand 1 Expression and Its Correlation with Lymph Node Metastasis in Papillary Thyroid Carcinoma
Hyo Jung An, Gyung Hyuck Ko, Jeong-Hee Lee, Jong Sil Lee, Dong Chul Kim, Jung Wook Yang, Min Hye Kim, Jin Pyeong Kim, Eun Jung Jung, Dae Hyun Song
Journal of Pathology and Translational Medicine.2018; 52(1): 9.     CrossRef
Radiological evaluation of response to immunotherapy in brain tumors: Where are we now and where are we going?
Michele Porcu, Cinzia Solinas, Paolo Garofalo, Evandro de Azambuja, Mario Scartozzi, Karen Willard-Gallo, Matthias Preusser, Luca Saba
Critical Reviews in Oncology/Hematology.2018; 126: 135.     CrossRef
The expression of programed death ligand-1 could be related with unfavorable prognosis in salivary duct carcinoma
Fumihiko Sato, Jun Akiba, Akihiko Kawahara, Yoshiki Naito, Takeharu Ono, Yorihiko Takase, Kazuya Murata, Hideyuki Abe, Tomohiko Yamaguchi, Hiroaki Miyoshi, Yushi Abe, Yutaro Mihara, Masahiko Tanikawa, Momoko Akashi, Hirofumi Kurose, Hirohito Umeno, Hirohi
Journal of Oral Pathology & Medicine.2018; 47(7): 683.     CrossRef
Expression Patterns, Prognostic Value, and Intratumoral Heterogeneity of PD-L1 and PD-1 in Thymoma and Thymic Carcinoma
Dwight Owen, Benjamin Chu, Amy M. Lehman, Lakshmanan Annamalai, Jennifer H. Yearley, Konstantin Shilo, Gregory A. Otterson
Journal of Thoracic Oncology.2018; 13(8): 1204.     CrossRef
PD-L1 and immune escape: insights from melanoma and other lineage-unrelated malignancies
Noah Frydenlund, Meera Mahalingam
Human Pathology.2017; 66: 13.     CrossRef
Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma
Russell Maxwell, Christopher M. Jackson, Michael Lim
Current Treatment Options in Oncology.2017;[Epub]     CrossRef
Topotecan Decreases the Expression of Programmed Death-Ligand 1 in Glioblastoma Cell Lines; Implications for Immunotherapy
Joshua Bernstock, Daniel Ye, Florian Gessler, Luca Peruzzotti-Jametti, Mark Gilbert, Yves Pommier, Stefano Pluchino, Ichiro Nakano, John Hallenbeck
Matters.2017;[Epub]     CrossRef